China National Accord Medicines Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St · 09/01 02:00

China National Accord Medicines (SZSE:000028) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥18.7b (down 5.1% from 2Q 2023).
  • Net income: CN¥354.7m (down 24% from 2Q 2023).
  • Profit margin: 1.9% (down from 2.4% in 2Q 2023). The decrease in margin was driven by lower revenue.
  • EPS: CN¥0.64 (down from CN¥0.84 in 2Q 2023).
earnings-and-revenue-growth
SZSE:000028 Earnings and Revenue Growth September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

China National Accord Medicines EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 1.6%.

Looking ahead, revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare industry in China.

Performance of the Chinese Healthcare industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 1 warning sign for China National Accord Medicines that you need to be mindful of.